The AMAG Pharmaceuticals Inc. (AMAG) Earns “Outperform” Rating from Leerink Swann

The AMAG Pharmaceuticals Inc. (AMAG) Earns “Outperform” Rating from Leerink Swann

Leerink Swann restated their outperform rating on shares of AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) in a report published on Thursday morning. The firm currently has a $36.00 target price on the specialty pharmaceutical company’s stock.

Several other equities research analysts have also recently issued reports on AMAG. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a strong sell rating to a hold rating in a research note on Tuesday, July 5th. Jefferies Group lowered their target price on shares of AMAG Pharmaceuticals from $58.00 to $45.00 and set a buy rating on the stock in a research note on Wednesday, August 10th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $36.33.

AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 24.05 on Thursday. AMAG Pharmaceuticals has a 12-month low of $17.92 and a 12-month high of $42.49. The stock has a 50 day moving average of $24.05 and a 200-day moving average of $23.97. The company’s market capitalization is $821.40 million.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.25. AMAG Pharmaceuticals had a negative net margin of 4.87% and a positive return on equity of 13.98%. The company had revenue of $127.40 million for the quarter, compared to analysts’ expectations of $128.52 million. During the same quarter in the previous year, the company posted $1.12 EPS. The firm’s quarterly revenue was up 46.7% on a year-over-year basis. Equities analysts expect that AMAG Pharmaceuticals will post $5.55 earnings per share for the current year.

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its stake in shares of AMAG Pharmaceuticals by 528.5% in the first quarter. BlackRock Inc. now owns 4,299 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 3,615 shares during the period. Teacher Retirement System of Texas raised its stake in shares of AMAG Pharmaceuticals by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 4,864 shares of the specialty pharmaceutical company’s stock worth $116,000 after buying an additional 589 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of AMAG Pharmaceuticals by 1,666.7% in the third quarter. Nisa Investment Advisors LLC now owns 5,300 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 5,000 shares during the period. Mason Street Advisors LLC acquired a new stake in shares of AMAG Pharmaceuticals during the second quarter worth about $162,000. Finally, Societe Generale acquired a new stake in shares of AMAG Pharmaceuticals during the second quarter worth about $232,000.

AMAG Pharmaceuticals Company Profile

Related posts

Leave a Comment